• Sunitinib Workflows for RCC Resistance Studies

  2026-08-14

  Build reproducible Sunitinib assays that connect RTK blockade with angiogenesis, apoptosis, cell-cycle control, and metabolic drug resistance. A practical workflow shows how to compare sensitive and resistant renal cell carcinoma models and test glycolysis-focused combination strategies.

• Structural Basis of P/Q-Type Cav2.1 Toxin Sensitivity

  2026-08-14

  The 2024 Cell Research study combines electrophysiology and near-atomic-resolution cryo-EM to explain why P-type and Q-type Cav2.1 channels respond differently to ω-agatoxin IVA. Its structures place the toxin at the extracellular voltage-sensing domain IV and connect alternative splicing in the S3–S4IV loop with altered toxin sensitivity, providing a mechanistic framework for selective Cav2.1 channel modulation.

• CF10–EdU Synergy Drives Telomere Attrition in CRC

  2026-08-13

  The reference study shows that the fluoropyrimidine polymer CF10 synergizes strongly with 5-ethynyl-2′-deoxyuridine (EdU), unlike the additive interaction observed with EdU plus 5-fluorouracil. The combination increases EdU incorporation, DNA double-strand breaks, telomere signal loss, cell-cycle disruption, and mitotic catastrophe in colorectal cancer models, providing a mechanistic framework for studying drug-induced telomere attrition.

• GS-441524 Workflows for Prodrug Conversion

  2026-08-13

  Build more informative antiviral and pharmacokinetic studies with GS-441524, from DMSO stock preparation to LC–MS/MS tracking across biological matrices. The workflow distinguishes parent-compound activity from prodrug conversion, helping researchers connect cell responses with exposure and metabolite formation.

• COX-2 in Venom-Induced Muscle Ischemia

  2026-08-12

  A Microvascular Research study shows that COX-2 has a time-dependent role after Bothrops asper venom injury: it helps preserve vascular integrity during acute ischemia, whereas early inhibition later enhances angiogenic and matrix-remodeling signals. The findings refine how selective COX-2 inhibition should be interpreted in muscle injury and revascularization models.

• LY2228820: Selective p38 MAP Kinase Inhibitor

  2026-08-12

  LY2228820 is a selective ATP-competitive p38 MAP kinase inhibitor that targets p38α and p38β with nanomolar biochemical potency. It supports mechanistic studies of p38 MAPK signaling, cytokine release, tumor biology, and bortezomib-associated cytotoxicity.

• L. gasseri, NR1I3, and E-Cadherin in Colitis

  2026-08-11

  This study identifies a mechanistic pathway in which Lactobacillus gasseri ATCC33323 protects against DSS-induced colitis by regulating NR1I3-associated CDH1 transcription and preserving E-cadherin-dependent epithelial barrier function. Its combination of probiotic intervention, intestinal E-cadherin loss-of-function models, transcriptional analysis, and in vitro validation provides a stronger causal framework than probiotic efficacy measurements alone.

• Dual Luciferase Reporter Gene System for Gene Regulation

  2026-08-11

  Use a firefly reporter to quantify promoter or enhancer activity while Renilla provides an internal normalization signal in the same sample. The APExBIO K1136 system adds a direct-to-cell workflow, compatible mammalian media, and spectrally distinct readouts for reproducible gene expression regulation studies.

• NBC19 and Metabolic Inflammation: Assay Logic

  2026-08-10

  NBC19 is a nanomolar NLRP3 inflammasome inhibitor for resolving how danger signals shape IL-1β biology. This article connects lactate–HMGB1 signaling in sepsis with practical assay decisions while distinguishing validated product performance from testable research hypotheses.

• Moesin as a Biomarker of Endothelial Injury in Sepsis

  2026-08-09

  The reference study identifies circulating moesin (MSN) as a potential marker of endothelial injury and sepsis severity, linking serum MSN to SOFA scores, procalcitonin, and experimental lung damage. Its combination of patient observations, mouse models, and endothelial-cell mechanistic assays suggests that MSN is both a biomarker candidate and a regulator of ROCK1/MLC and NF-κB-associated barrier dysfunction.

• AMPK–p62 Feedback Under Metabolic Stress

  2026-08-08

  The 2024 Autophagy study identifies a double-positive feedback loop in which AMPK and SQSTM1/p62 reinforce one another during metabolic stress, jointly activating AMPK and NFE2L2/NRF2 antioxidant programs. Its mechanistic model connects lysosomal pH, calcium release, ROS, TFEB/TFE3, TAK1, KEAP1 degradation, and tumor adaptation, while also clarifying why STK11 and KEAP1 pathway alterations can be functionally complementary in NSCLC.

• NF 449 as a Selective P2X1 Antagonist

  2026-08-07

  The reference study identified NF 449 as an exceptionally potent antagonist of recombinant rat P2X1-containing receptors by systematically profiling homomeric and heteromeric P2X channels. Its electrophysiological design established a useful benchmark for distinguishing P2X1-mediated ATP signaling from activity at related receptor subtypes, while also defining the limits of translating recombinant-receptor data to platelet and antithrombotic research.

• Discovery and Characterization of MK 0893 as a Glucagon Rece

  2026-08-07

  The reference study details the rational design and preclinical evaluation of MK 0893, a potent and selective glucagon receptor antagonist. This work provides foundational insights into pharmacophore optimization, selectivity profiling, and in vivo efficacy for type 2 diabetes research.

• BI 2536: Unveiling PLK1 Inhibition for Translational Cancer

  2026-08-06

  This thought-leadership article explores how BI 2536, a potent and selective PLK1 inhibitor, enables advanced mechanistic and translational cancer research. Integrating recent in vitro evaluation paradigms and scenario-driven assay solutions, it delivers strategic guidance for researchers seeking robust, reproducible, and clinically meaningful insights into cell cycle regulation, apoptosis, and tumor biology.

• Antibody Targeting of SCUBE3 Suppresses Cancer Progression

  2026-08-06

  The reference study identifies secretory SCUBE3 as a key driver of cancer growth, therapy resistance, and immune evasion. By developing a neutralizing antibody against SCUBE3, the research demonstrates effective suppression of oncogenic signaling and restoration of antitumor immunity, offering a promising strategy for pan-cancer therapy.

16395 records 1/1093 page Next 12345 下5页 Last page